Debrisoquine oxidation phenotype during neuroleptic monotherapy

POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN

1977 • 1,196 citations

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

1979 • 647 citations

The P450 Superfamily: Updated Listing of All Genes and Recommended Nomenclature for the Chromosomal Loci

1989 • 609 citations

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1980 • 544 citations

The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects

1990 • 367 citations

Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

1990 • 363 citations

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

1989 • 292 citations

Recent Developments in Hepatic Drug Oxidation

1990 • 189 citations

Drug Interaction: Inhibitory Effect of Neuroleptics on Metabolism of Tricyclic Antidepressants in Man

1972 • 176 citations

In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.

1985 • 173 citations

Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in luman beings

1989 • 167 citations

Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection

1977 • 155 citations

A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin

1985 • 127 citations

Xenobiotic and endobiotic inhibitors of cytochrome p-450dbl function, the target of the debrisoouine/sparteine type polymorphism

1988 • 113 citations

Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.

1986 • 94 citations

Extensive Metabolizers of Debrisoquine Become Poor Metabolizers during Quinidine Treatment

1987 • 92 citations

Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes

1985 • 91 citations

Genetically determined polymorphisms in drug oxidation

1986 • 88 citations

Inhibitory effects of neuroleptics on debrisoquine oxidation in man.

1986 • 79 citations

Plasma concentrations of nortriptyline and its 10‐hydroxy metabolite in depressed patients‐relationship to the debrisoquine hydroxylation metabolic ratio.

1985 • 69 citations

Substantial rise in sparteine metabolic ratio during haloperidol treatment.

1989 • 58 citations

Antipsychotic Drugs

1987 • 52 citations

Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine

1986 • 41 citations

Debrisoquine oxidative phenotyping and psychiatric drug treatment

1989 • 28 citations

The effects of beta‐adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine.

1990 • 20 citations

Clinical pharmacology in psychiatry : from molecular studies to clinical reality

1989 • 15 citations

Positive antinuclear factor tests with prazosin.

1979 • 14 citations

The Use of Human Liver Banks in Pharmacogenetic Research

1989 • 13 citations

Debrisoquine Oxidation Phenotype in Psychiatric Patients

1989 • 9 citations

Diazepam Treatment Does Not Influence the Debrisoquine or Mephenytoin Hydroxylation Phenotyping Tests

1989 • 6 citations

Deleted Work

1955 • 0 citations